Clinical Trials on Chronic Progressive External Ophthalmoplegia in Sweden

Total 17 results

Karolinska Institutet

Completed

Mesenchymal Stem Cells for Progressive Multiple Sclerosis_Sweden

Multiple Sclerosis | Autologous Mesenchymal Stem Cells

Sweden
Anders Svenningsson
Västerbotten County Council, Sweden

Completed

Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis (ITT-PMS)

Progressive Multiple Sclerosis

Sweden
Skane University Hospital
Lund University

Recruiting

The Swedish BioFINDER 2 Study (BioFINDER2)

Parkinson Disease | Dementia | Alzheimer Disease | Frontotemporal Degeneration | Mild Cognitive Impairment | Lewy Body Disease | Multiple System Atrophy | Corticobasal Degeneration | Progressive Supranuclear Palsy | Semantic Dementia | Parkinson-Dementia Syndrome | Progressive Nonfluent Aphasia

Sweden
Skane University Hospital
AC Immune SA

Completed

Optimization of Morphomer-based Alpha-synuclein PET Tracers

Parkinson Disease | Multiple System Atrophy | Corticobasal Degeneration | Progressive Supranuclear Palsy | Dementia With Lewy Bodies

Sweden
Bayer

Withdrawn

Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS)

Multiple Sclerosis

Sweden, Denmark
EpiEndo Pharmaceuticals
CTC Clinical Trial Consultants AB

Completed

Clinical Trial to Assess Effect of Verapamil on Systemic Exposure of EP395 and Effect of EP395 on Systemic Exposure of Midazolam and Digoxin

COPD | Chronic Obstructive Pulmonary Disease Exacerbation

Sweden
Eli Lilly and Company
BioMS Technology Corp.

Completed

A Study for Patients With Secondary Progressive Multiple Sclerosis (MAESTRO-01)

Secondary Progressive Multiple Sclerosis

Canada, Estonia, Denmark, Finland, Germany, Latvia, Netherlands, Spain, Sweden, United Kingdom
Eli Lilly and Company
BioMS Technology Corp.

Terminated

A Study for Patients With Multiple Sclerosis (MAESTRO-02)

Secondary Progressive Multiple Sclerosis

Canada, Estonia, Denmark, Finland, Latvia, Spain, Sweden, United Kingdom, Germany, Netherlands
Genentech, Inc.

Completed

Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)

Multiple Sclerosis, Primary Progressive | Relapsing Multiple Sclerorsis

United States, Germany, Canada, Sweden
AB Science

Recruiting

Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis (MAXIMS)

Progressive Multiple Sclerosis

Spain, Sweden, France, Greece, Italy, Poland, Russian Federation, Ukraine
Heidelberg University
Baxter Healthcare Corporation; Boehringer Ingelheim; Aventis Pharmaceuticals; European...

Completed

Effect of Strict Blood Pressure Control and ACE-Inhibition on Progression of Chronic Renal Failure in Pediatric Patients (ESCAPE)

Hypertension | Children | Chronic Renal Failure | Acquired Kidney Disease | Congenital Kidney Disease

Czech Republic, France, Germany, Hungary, Italy, Lithuania, Poland, Portugal, Serbia, Sweden, Switzerland, Turkey
Wim Janssens
Roche Pharma AG; AstraZeneca; European Respiratory Society

Recruiting

The CATALINA Study

Chronic Obstructive Pulmonary Disease Exacerbation

Belgium, Spain, Sweden, Netherlands, France, Germany, Italy, United Kingdom
Sanofi

Recruiting

Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS) (PERSEUS)

Primary Progressive Multiple Sclerosis

Spain, Italy, Turkey, India, Israel, Bulgaria, Mexico, Greece, Portugal, United States, Argentina, Australia, Austria, Belarus, Belgium, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Estonia, France, Georgia, Germany, Hungary, Japan and more
MedDay Pharmaceuticals SA

Terminated

Effect of MD1003 in Progressive Multiple Sclerosis (SPI2) (SPI2)

Multiple Sclerosis

United States, Spain, Canada, Australia, United Kingdom, Belgium, Turkey, Czechia, Poland, Italy, Hungary, Germany, Sweden
Novartis Pharmaceuticals

Completed

Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)

Secondary Progressive Multiple Sclerosis

China, Germany, United States, Romania, Italy, Austria, Belgium, Czechia, Spain, Australia, Canada, France, Israel, Switzerland, Bulgaria, Hungary, Netherlands, United Kingdom, Estonia, Latvia, Lithuania, Russian Federation, Turkey, J... and more
Novartis Pharmaceuticals

Terminated

This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS. (INFORMS)

Primary Progressive Multiple Sclerosis

United States, Belgium, Poland, Germany, Hungary, Turkey, Spain, Australia, Canada, Czechia, Switzerland, United Kingdom, Netherlands, France, Italy, Denmark, Finland, Sweden
Biogen

Terminated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis (ASCEND in SPMS)

Secondary Progressive Multiple Sclerosis

United States, Finland, Italy, Spain, Canada, France, Israel, Sweden, Netherlands, Belgium, Poland, United Kingdom, Czechia, Denmark, Russian Federation, Germany, Ireland

Clinical Trials on Chronic Progressive External Ophthalmoplegia in Sweden

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Togo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations